Date receipt dossier
EudraCT number
2016-001706-42
Company / Sponsor
Celgene
Phase
II
Treated organism
Humans
Indication category
Cancer therapy
Disease
Acute lymphoblastic leukemia
Therapeutic approach
Immunotherapy
Genetic modification
Chimeric antigen receptor against CD19
Method of transfer of nucleic acid of interest
Gamma-retroviral vectors
Administered biological material
T-cells transduced with gamma-retroviral vectors to express chimeric antigen receptor (CAR) against CD19
Route of administration
Intravenous
Locations in Belgium
UZ Gent
Nr of subjects
25 participants
Type of procedure
Contained use only
Current status
Authorized